← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
  1. Home
  2. AMGN
  3. P/E History
OverviewAnalysisPriceRevenueEarningsP/ERatiosDividendTargetsShould I Buy?

AMGN logoAmgen Inc. (AMGN) P/E Ratio History

Historical price-to-earnings valuation from 1990 to 2026

Current P/E
23.3
Fair Value
5Y Avg P/E
25.8
-10% vs avg
PE Percentile
60%
Above Avg
PEG Ratio
7.91
Expensive
TTM EPS$14.34
Price$331.11
5Y PE Range15.0 - 53.8
Earnings Yield4.30%

Loading P/E history...

AMGN Valuation Context

How does the current P/E compare to historical and market benchmarks?

vs. 5Y Average
23.3vs25.8
-10%
In Line with History
vs. Healthcare
23.3vs22.1
+5%
In Line with Sector
vs. S&P 500
23.3vs25.2
-8%
In Line with Market
PEG Analysis
7.91
P/E ÷ EPS Growth
PEG > 2 = Expensive
Based on 88% EPS growth (1Y)
Export Data

P/E Ratio Analysis

As of May 7, 2026, Amgen Inc. (AMGN) trades at a price-to-earnings ratio of 23.3x, with a stock price of $331.11 and trailing twelve-month earnings per share of $14.34.

The current P/E is roughly in line with its 5-year average of 25.8x. Over the past five years, AMGN's P/E has ranged from a low of 15.0x to a high of 53.8x, placing the current valuation at the 60th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, AMGN is roughly in line with its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.

The PEG ratio of 7.91 (P/E divided by 88% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.

Relative to the broader market, AMGN trades roughly in line with the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our AMGN DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

AMGN P/E vs Peers

P/E ratio compared to closely matched public peers

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
GILD logoGILDGilead Sciences, Inc.
$170B358.7--92%
BIIB logoBIIBBiogen Inc.
$28B21.6--21%
REGN logoREGNRegeneron Pharmaceuticals, Inc.
$75B17.42.75+8%
VRTX logoVRTXVertex Pharmaceuticals Incorporated
$109B27.93.37+837%Best
BMY logoBMYBristol-Myers Squibb Company
$115B16.4-+178%
LLY logoLLYEli Lilly and Company
$933B43.01.49+96%
ABBV logoABBVAbbVie Inc.
$363B86.5--1%
MRK logoMRKMerck & Co., Inc.
$280B15.6Lowest0.73Best+8%
PFE logoPFEPfizer Inc.
$151B19.5--4%
JNJ logoJNJJohnson & Johnson
$541B38.8--58%

Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.

AMGN Historical P/E Data (1990–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterDatePriceTTM EPSP/E Ratiovs Avg
FY2026 Q1$351.85$14.3724.5x-14%
FY2025 Q4Wed Dec 31 2025 00:00:00 GM$327.31$14.2323.0x-19%
FY2025 Q3$282.20$12.9421.8x-23%
FY2025 Q2Mon Jun 30 2025 00:00:00 GM$279.21$12.2322.8x-20%
FY2025 Q1Mon Mar 31 2025 00:00:00 GM$311.55$10.9628.4x+0%
FY2024 Q4$260.64$7.5534.5x+22%
FY2024 Q3Mon Sep 30 2024 00:00:00 GM$322.21$7.8141.3x+45%
FY2024 Q2Sun Jun 30 2024 00:00:00 GM$312.45$5.8153.8x+89%
FY2024 Q1Sun Mar 31 2024 00:00:00 GM$284.32$7.0040.6x+43%
FY2023 Q4Sun Dec 31 2023 00:00:00 GM$288.02$12.4923.1x-19%
FY2023 Q3Sat Sep 30 2023 00:00:00 GM$268.76$14.0719.1x-33%
FY2023 Q2Fri Jun 30 2023 00:00:00 GM$222.02$14.8315.0x-47%

Average P/E for displayed period: 28.4x

Full AMGN Stock Analysis

Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.

View Analysis

Should I Buy AMGN Right Now?

Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.

See Verdict

See AMGN's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is AMGN Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare AMGN vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

AMGN — Frequently Asked Questions

Quick answers to the most common questions about buying AMGN stock.

Is AMGN stock overvalued or undervalued?

AMGN trades at 23.3x P/E, near its 5-year average of 25.8x. The 60th percentile ranking places valuation within normal historical bounds.

How does AMGN's valuation compare to peers?

Amgen Inc. P/E of 23.3x compares to sector median of 22.1x. The premium reflects expected growth above peers.

What is AMGN's PEG ratio?

AMGN PEG ratio is 7.91. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 1990-2026.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.

AMGN P/E Ratio History (1990–2026)

P/E ratio calculated as closing price divided by trailing 12-month diluted EPS at each quarter end.